Abramson JS et al. Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): A global phase 3, randomised, open-label trial. Lancet 2024;404(10466):1940-54. Abstract
Brem E et al. Odronextamab monotherapy in previously untreated patients with high-risk follicular lymphoma (FL): Results of the safety lead-in of the phase 3 Olympia-1 study. ASH 2024;Abstract 4411.
Dickinson MJ et al. Fixed-duration glofitamab monotherapy continues to demonstrate durable responses in patients with relapsed or refractory large b-cell lymphoma: 3-year follow-up from a pivotal phase II study. ASH 2024;Abstract 865.
Dreyling M et al. High-risk subgroups and MRD: An updated analysis of the phase 3 ECHO trial of acalabrutinib with bendamustine/rituximab in previously untreated mantle cell lymphoma. ASH 2024;Abstract 1626.
Dreyling M et al. Role of autologous stem cell transplantation in the context of ibrutinib-containing first-line treatment in younger patients with mantle cell lymphoma: Results from the randomized Triangle trial by the European MCL network. ASH 2024;Abstract 240.
Falchi L et al. Single-agent mosunetuzumab produces high complete response rates in patients with newly diagnosed follicular lymphoma: Primary analysis of the Mithic-FL1 trial. ASH 2024;Abstract 340.
Fenske TS et al. Lack of benefit of autologous hematopoietic cell transplantation (auto-HCT) in mantle cell lymphoma (MCL) patients (pts) in first complete remission (CR) with undetectable minimal residual disease (uMRD): Initial report from the ECOG-ACRIN EA4151 phase 3 randomized trial. ASH 2024;Abstract LBA-6.
Gaballa S et al. Evaluation of AZD0486, a novel CD19xCD3 T-cell engager, in relapsed/refractory diffuse large b-cell lymphoma in an ongoing first-in-human phase 1 study: High complete responses seen in CAR-T-naive and CAR-T-exposed patients. ASH 2024;Abstract 868.
Gregory GP et al. Primary results of patient-reported outcomes in patients with relapsed/refractory diffuse large B-cell lymphoma treated with glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) versus rituximab plus GemOx (R-GemOx) from the phase III Starglo study. ASH 2024;Abstract 5132.
Hou J-Z et al. Escalating doses of AZD0486, a novel CD19xCD3 T-cell engager, result in high complete remissions with rapid clearance of minimal residual disease in patients with relapsed/refractory follicular lymphoma. ASH 2024;Abstract 341.
Jerkeman M et al. Acalabrutinib and rituximab in elderly patients with newly diagnosed mantle cell lymphoma including a matched population-based external comparator- the nordic lymphoma group NLG-MCL8 (ALTAMIRA) phase II trial. ASH 2024;Abstract 747.
Ladetto M et al. Impact of rituximab maintenance added to ibrutinib-containing regimens with and without ASCT in younger, previously untreated MCL patients: An analysis of the Triangle data embedded in the Multiply project. ASH 2024;Abstract 237.
Lewis D et al. Ibrutinib-rituximab is superior to rituximab-chemotherapy in previously untreated older mantle cell lymphoma patients: Results from the international randomised controlled trial, Enrich. ASH 2024;Abstract 235.
Matasar M et al. Efficacy and safety of odronextamab monotherapy in patients (Pts) with diffuse large B-cell lymphoma (DLBCL) progressing after CAR T-cell therapy: Primary analysis from the ELM-1 study. ASH 2024;Abstract 866.
Morschhauser F et al. Epcore DLBCL-3 first disclosure: Fixed-duration epcoritamab monotherapy in older (≥75 y), anthracycline-ineligible patients with previously untreated large B-cell lymphoma. ASH 2024;Abstract 867.
Neelapu SS et al. 5-year follow-up analysis from ZUMA-5: A phase 2 trial of axicabtagene ciloleucel (Axi-Cel) in patients with relapsed/refractory indolent non-Hodgkin lymphoma. ASH 2024;Abstract 864.
Schuster SJ. Bispecific antibodies for the treatment of lymphomas: Promises and challenges. Hematol Oncol 2021;39(Suppl 1):113-6. Abstract
Sehn LH et al. Tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: Results from a phase 3 study (inMIND). ASH 2024;Abstract LBA-1.
Shadman M et al. Mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed and/or refractory follicular lymphoma after ≥2 prior therapies including those with a history of POD24: 4-year follow-up of a pivotal phase II study. ASH 2024;Abstract 4407.
Stepan L et al. Circulating tumor DNA (ctDNA) as an early outcome predictor in patients (pts) with second-line (2L) large b-cell lymphoma (LBCL) after lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) treatment (tx) from the phase 3, randomized Transform study. ASH 2024;Abstract 72.
Tilly H et al. Polatuzumab vedotin in previously untreated diffuse large b-cell lymphoma. N Engl J Med 2022;386(4):351-63. Abstract
Wagner-Johnstone ND et al. Addition or substitution of acalabrutinib in intensive frontline chemoimmunotherapy for patients ≤ 70 years old with mantle cell lymphoma: Outcomes of the 3-arm randomized phase II intergroup trial ECOG-ACRIN EA4181. ASH 2024;Abstract 236.
Wang M et al. Acalabrutinib plus bendamustine and rituximab in untreated mantle cell lymphoma: Results from the phase 3, double-blind, placebo-controlled ECHO trial. EHA 2024;Abstract LB3439.